Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gap junction protein epsilon-1 (GJE1), also known as Connexin-23 (Cx23), is a member of the connexin family of transmembrane proteins that form gap junctions—specialized intercellular channels enabling direct communication between adjacent cells[1][3][4]. Unlike most connexins, GJE1 is predicted to act as a hemichannel mediating calcium-independent ATP release but does not form functional, cell-cell spanning gap junctions[1]. It is involved in processes such as cell-cell signaling, lens development, organ growth, and cell morphogenesis, and is typically expressed at the plasma membrane as part of connexin complexes[1][3]. Mutations in this gene have been associated with rare inherited defects such as autosomal recessive deafness and palmoplantar keratoderma with deafness[1]. While the broader connexin family is often studied as a target class, there is currently no known evidence that GJE1 specifically serves as a direct therapeutic target[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gap junction protein epsilon-1 (GJE1).